Selected research
Industry Research
Taditional Chinese Medicine (TCM) for COVID-19 Industry Research Report 2026
Market perspective
The global Taditional Chinese Medicine (TCM) for COVID-19 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Taditional Chinese Medicine (TCM) for COVID-19 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Taditional Chinese Medicine (TCM) for COVID-19 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Taditional Chinese Medicine (TCM) for COVID-19 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Taditional Chinese Medicine (TCM) for COVID-19 include China Beijing Tong Ren Tang Group Co., Ltd., Yiling Pharmaceutical, Southwest Pharmaceutical, Beijing Juxiechang Pharmaceutical, Jiuzhitang, Jiangsu Jichuan Holding Group Co., Ltd., Tianjin Chase Sun Pharmaceutical, Guizhou Yibai Pharmaceutical and Sunflower, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Taditional Chinese Medicine (TCM) for COVID-19 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Taditional Chinese Medicine (TCM) for COVID-19.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Taditional Chinese Medicine (TCM) for COVID-19 Market by Company
China Beijing Tong Ren Tang Group Co., Ltd.
Yiling Pharmaceutical
Southwest Pharmaceutical
Beijing Juxiechang Pharmaceutical
Jiuzhitang
Jiangsu Jichuan Holding Group Co., Ltd.
Tianjin Chase Sun Pharmaceutical
Guizhou Yibai Pharmaceutical
Sunflower
Qingfeng Pharmaceutical Group
Jiren Pharmaceutical Group
Taditional Chinese Medicine (TCM) for COVID-19 Segment by Type
Jinhua Qinggan Granules
Lianhua Qingwen Capsule
Xuebijing Injection
TCM Prescription
Other
Taditional Chinese Medicine (TCM) for COVID-19 Segment by Application
Hospital
Clinic
Other
Taditional Chinese Medicine (TCM) for COVID-19 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Taditional Chinese Medicine (TCM) for COVID-19 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Taditional Chinese Medicine (TCM) for COVID-19 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Taditional Chinese Medicine (TCM) for COVID-19.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Taditional Chinese Medicine (TCM) for COVID-19 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Jinhua Qinggan Granules
- Lianhua Qingwen Capsule
- Xuebijing Injection
- TCM Prescription
- Other
Applications
- Hospital
- Clinic
- Other
Companies covered
- China Beijing Tong Ren Tang Group Co., Ltd.
- Yiling Pharmaceutical
- Southwest Pharmaceutical
- Beijing Juxiechang Pharmaceutical
- Jiuzhitang
- Jiangsu Jichuan Holding Group Co., Ltd.
- Tianjin Chase Sun Pharmaceutical
- Guizhou Yibai Pharmaceutical
- Sunflower
- Qingfeng Pharmaceutical Group
- Jiren Pharmaceutical Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Taditional Chinese Medicine (TCM) for COVID-19 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Jinhua Qinggan Granules
- 2.2.3 Lianhua Qingwen Capsule
- 2.2.4 Xuebijing Injection
- 2.2.5 TCM Prescription
- 2.2.6 Other
- 2.3 Taditional Chinese Medicine (TCM) for COVID-19 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Taditional Chinese Medicine (TCM) for COVID-19 Breakdown Data by Type
- 3.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Historic Market Size by Type (2021-2026)
- 3.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Forecasted Market Size by Type (2027-2032)
4 Taditional Chinese Medicine (TCM) for COVID-19 Breakdown Data by Application
- 4.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Historic Market Size by Application (2021-2026)
- 4.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Market Perspective (2021-2032)
- 5.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Growth Trends by Region
- 5.2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Taditional Chinese Medicine (TCM) for COVID-19 Historic Market Size by Region (2021-2026)
- 5.2.3 Taditional Chinese Medicine (TCM) for COVID-19 Forecasted Market Size by Region (2027-2032)
- 5.3 Taditional Chinese Medicine (TCM) for COVID-19 Market Dynamics
- 5.3.1 Taditional Chinese Medicine (TCM) for COVID-19 Industry Trends
- 5.3.2 Taditional Chinese Medicine (TCM) for COVID-19 Market Drivers
- 5.3.3 Taditional Chinese Medicine (TCM) for COVID-19 Market Challenges
- 5.3.4 Taditional Chinese Medicine (TCM) for COVID-19 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Taditional Chinese Medicine (TCM) for COVID-19 Players by Revenue
- 6.1.1 Global Top Taditional Chinese Medicine (TCM) for COVID-19 Players by Revenue (2021-2026)
- 6.1.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Revenue Market Share by Players (2021-2026)
- 6.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Taditional Chinese Medicine (TCM) for COVID-19 Head Office and Area Served
- 6.4 Global Taditional Chinese Medicine (TCM) for COVID-19 Players, Product Type & Application
- 6.5 Global Taditional Chinese Medicine (TCM) for COVID-19 Manufacturers Established Date
- 6.6 Global Taditional Chinese Medicine (TCM) for COVID-19 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Taditional Chinese Medicine (TCM) for COVID-19 Market Size (2021-2032)
- 7.2 North America Taditional Chinese Medicine (TCM) for COVID-19 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2021-2026)
- 7.4 North America Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Taditional Chinese Medicine (TCM) for COVID-19 Market Size (2021-2032)
- 8.2 Europe Taditional Chinese Medicine (TCM) for COVID-19 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2021-2026)
- 8.4 Europe Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Market Size (2021-2032)
- 9.2 Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Taditional Chinese Medicine (TCM) for COVID-19 Market Size (2021-2032)
- 10.2 South America Taditional Chinese Medicine (TCM) for COVID-19 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2021-2026)
- 10.4 South America Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Market Size (2021-2032)
- 11.2 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 China Beijing Tong Ren Tang Group Co., Ltd.
- 12.1.1 China Beijing Tong Ren Tang Group Co., Ltd. Company Information
- 12.1.2 China Beijing Tong Ren Tang Group Co., Ltd. Business Overview
- 12.1.3 China Beijing Tong Ren Tang Group Co., Ltd. Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.1.4 China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.1.5 China Beijing Tong Ren Tang Group Co., Ltd. Recent Developments
- 12.2 Yiling Pharmaceutical
- 12.2.1 Yiling Pharmaceutical Company Information
- 12.2.2 Yiling Pharmaceutical Business Overview
- 12.2.3 Yiling Pharmaceutical Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.2.4 Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.2.5 Yiling Pharmaceutical Recent Developments
- 12.3 Southwest Pharmaceutical
- 12.3.1 Southwest Pharmaceutical Company Information
- 12.3.2 Southwest Pharmaceutical Business Overview
- 12.3.3 Southwest Pharmaceutical Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.3.4 Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.3.5 Southwest Pharmaceutical Recent Developments
- 12.4 Beijing Juxiechang Pharmaceutical
- 12.4.1 Beijing Juxiechang Pharmaceutical Company Information
- 12.4.2 Beijing Juxiechang Pharmaceutical Business Overview
- 12.4.3 Beijing Juxiechang Pharmaceutical Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.4.4 Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.4.5 Beijing Juxiechang Pharmaceutical Recent Developments
- 12.5 Jiuzhitang
- 12.5.1 Jiuzhitang Company Information
- 12.5.2 Jiuzhitang Business Overview
- 12.5.3 Jiuzhitang Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.5.4 Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.5.5 Jiuzhitang Recent Developments
- 12.6 Jiangsu Jichuan Holding Group Co., Ltd.
- 12.6.1 Jiangsu Jichuan Holding Group Co., Ltd. Company Information
- 12.6.2 Jiangsu Jichuan Holding Group Co., Ltd. Business Overview
- 12.6.3 Jiangsu Jichuan Holding Group Co., Ltd. Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.6.4 Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.6.5 Jiangsu Jichuan Holding Group Co., Ltd. Recent Developments
- 12.7 Tianjin Chase Sun Pharmaceutical
- 12.7.1 Tianjin Chase Sun Pharmaceutical Company Information
- 12.7.2 Tianjin Chase Sun Pharmaceutical Business Overview
- 12.7.3 Tianjin Chase Sun Pharmaceutical Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.7.4 Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.7.5 Tianjin Chase Sun Pharmaceutical Recent Developments
- 12.8 Guizhou Yibai Pharmaceutical
- 12.8.1 Guizhou Yibai Pharmaceutical Company Information
- 12.8.2 Guizhou Yibai Pharmaceutical Business Overview
- 12.8.3 Guizhou Yibai Pharmaceutical Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.8.4 Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.8.5 Guizhou Yibai Pharmaceutical Recent Developments
- 12.9 Sunflower
- 12.9.1 Sunflower Company Information
- 12.9.2 Sunflower Business Overview
- 12.9.3 Sunflower Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.9.4 Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.9.5 Sunflower Recent Developments
- 12.10 Qingfeng Pharmaceutical Group
- 12.10.1 Qingfeng Pharmaceutical Group Company Information
- 12.10.2 Qingfeng Pharmaceutical Group Business Overview
- 12.10.3 Qingfeng Pharmaceutical Group Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.10.4 Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.10.5 Qingfeng Pharmaceutical Group Recent Developments
- 12.11 Jiren Pharmaceutical Group
- 12.11.1 Jiren Pharmaceutical Group Company Information
- 12.11.2 Jiren Pharmaceutical Group Business Overview
- 12.11.3 Jiren Pharmaceutical Group Revenue in Taditional Chinese Medicine (TCM) for COVID-19 Business (2021-2026)
- 12.11.4 Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
- 12.11.5 Jiren Pharmaceutical Group Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst